Stocks › COGT

Cogent Biosciences, Inc.

COGT·Nasdaq·United States United States·USD
$26.71
-1.02 (-3.70%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
COGT
Cogent Biosciences, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
COGTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of COGT by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Christopher L. JacobsChristopher L. JacobsHouse · R · NY COGTCogent Biosciences, Inc. · Stock Purchase
$1,001 - $15,000
Jan 20, 2023 Dec 12, 2022 Filing ↗

Whale Activity

Position changes in COGT reported for 2026-09-30 by 373 institutional filers
Increased: 132New: 47Held: 39Decreased: 86Closed: 58No prior filing: 11
  • Increased132
  • New47
  • Held39
  • Decreased86
  • Closed58
  • No prior filing11
FilerSharesValueChange
FMR LLC26.9M$859.8Mincreased
BlackRock, Inc.17.2M$551.7Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC8.1M$260.4Mincreased
STATE STREET CORP7.8M$248.8Mincreased
VANGUARD CAPITAL MANAGEMENT LLC7.4M$238.5Mincreased
Janus Henderson Group Ltd.7.4M$238.0M—
DEERFIELD MANAGEMENT COMPANY, L.P.6.0M$190.7Mincreased
Fairmount Funds Management LLC5.5M$176.2Mheld
WELLINGTON MANAGEMENT GROUP LLP4.7M$149.8Mincreased
GEODE CAPITAL MANAGEMENT, LLC4.5M$143.4Mdecreased
PRICE T ROWE ASSOCIATES INC /MD/4.1M$132.4Mdecreased
Kynam Capital Management, LP3.8M$121.4Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by COGT insiders, by quarter · Form 4
-20.0M-10.0M010.0M20.0M2025 Q1: 43.8K2025 Q12025 Q2: 02025 Q22025 Q3: 2.8M2025 Q32025 Q4: -314.6K2025 Q42026 Q1: -10.5M2026 Q12026 Q2: 02026 Q22026 Q3: -45.5K2026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

500 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Morris ArleneDirector Sale −3,161 $37.54 $119K Aug 27, 2026 Form 4 ↗
Morris ArleneDirector Sale −42.3K $37.09 $1.6M Aug 27, 2026 Form 4 ↗
Morris ArleneDirector Option exercise +3,583 $2.52 $9K Aug 27, 2026 Form 4 ↗
Morris ArleneDirector Option exercise +41.9K $5.64 $236K Aug 27, 2026 Form 4 ↗
Robbins Andrew RPresident and CEO · Director Gift +160.0K $0.00 $0 May 19, 2026 Form 4 ↗
Robbins Andrew RPresident and CEO · Director Gift −160.0K $0.00 $0 May 19, 2026 Form 4 ↗
Fairmount Funds Management LLCDirector Sale −7.0M $34.66 $242.6M Mar 31, 2026 Form 4 ↗
Fairmount Funds Management LLCDirector Conversion +7.0M — — Mar 31, 2026 Form 4 ↗
Fairmount Funds Management LLCDirector Sale −3.5M $36.40 $127.4M Jan 22, 2026 Form 4 ↗
Kearns EvanChief Legal Officer Sale −65.0K $38.70 $2.5M Dec 26, 2025 Form 4 ↗
Green John L.Chief Financial Officer Sale −77.0K $38.68 $3.0M Dec 26, 2025 Form 4 ↗
Sachs JessicaChief Medical Officer Sale −82.6K $38.70 $3.2M Dec 26, 2025 Form 4 ↗
Robinson John EdwardChief Scientific Officer Sale −90.0K $38.74 $3.5M Dec 26, 2025 Form 4 ↗
Robinson John EdwardChief Scientific Officer Tax withholding −140.0K $39.45 $5.5M Dec 17, 2025 Form 4 ↗
Robinson John EdwardChief Scientific Officer Grant / award +320.0K $0.00 $0 Dec 17, 2025 Form 4 ↗
Robinson John EdwardChief Scientific Officer Grant / award +50.0K $0.00 $0 Dec 17, 2025 Form 4 ↗
Robbins Andrew RPresident and CEO · Director Tax withholding −367.5K $39.45 $14.5M Dec 17, 2025 Form 4 ↗
Robbins Andrew RPresident and CEO · Director Grant / award +840.0K $0.00 $0 Dec 17, 2025 Form 4 ↗
Robbins Andrew RPresident and CEO · Director Grant / award +185.0K $0.00 $0 Dec 17, 2025 Form 4 ↗
Pinnow ColeChief Commercial Officer Tax withholding −94.8K $39.45 $3.7M Dec 17, 2025 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding COGT · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
5.2M$199.6M0.01%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
4.3M$165.6M0.20%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
3.7M$144.1M0.08%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
3.2M$122.8M1.14%Jun 30, 2026
Fidelity Small Cap Growth Fund
Fidelity Securities Fund
2.5M$97.7M1.11%Jul 31, 2026
VANGUARD SMALL-CAP VALUE INDEX FUND
VANGUARD INDEX FUNDS
2.4M$91.3M0.13%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.0M$75.8M0.08%Jun 30, 2026
Fidelity OTC Portfolio
Fidelity Securities Fund
1.9M$72.9M0.17%Jul 31, 2026
Fidelity Advisor Biotechnology Fund
Fidelity Advisor Series VII
1.8M$71.4M3.25%Jul 31, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.8M$70.9M0.21%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list COGT's shares (CUSIP 19240Q201), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • James E. FlynnSCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
    Aug 13, 2026 · ↗
  • Deerfield Partners, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
    Aug 13, 2026 · ↗
  • Deerfield Management Company, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
    Aug 13, 2026 · ↗
  • Deerfield Mgmt, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
    Aug 13, 2026 · ↗
  • Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 8.7M shares5.1%
    Jul 31, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 13.6M shares8.0%
    Jul 27, 2026 · ↗
  • James E. FlynnSCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
    May 14, 2026 · ↗
  • Deerfield Partners, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
    May 14, 2026 · ↗
  • Deerfield Management Company, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
    May 14, 2026 · ↗
  • Deerfield Mgmt, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
    May 14, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Cogent Biosciences, Inc. as client

No lobbying filings found naming Cogent Biosciences, Inc. as the client.

Government Contracts

Federal awards to Cogent Biosciences, Inc. · USAspending

No federal contract awards found for Cogent Biosciences, Inc..

U.S. Patents

Recent USPTO applications naming Cogent Biosciences, Inc.

No USPTO patent applications found for Cogent Biosciences, Inc..

Annual Financials

From COGT's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income-$333.4M-$275.9M-$208.1M-$147.8M-$75.6M
Net income-$328.9M-$255.9M-$192.4M-$140.2M-$72.3M
Diluted EPS-$2.16-$1.94-$1.94-$1.73-$1.87
Operating cash flow-$264.4M-$207.8M-$153.6M-$118.6M-$58.8M
Cash and equivalents$312.0M$98.2M$53.2M$139.9M$219.7M
Total assets$937.6M$327.9M$313.4M$300.8M$232.1M
Total liabilities$301.2M$71.6M$55.6M$45.1M$17.9M
Shareholders' equity$636.4M$256.3M$257.8M$255.7M$214.2M

As Cogent Biosciences, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 17, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-4Reverse splitNov 9, 2020

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
    EDGAR ↗
  • 8-K · Items 1.01Material agreementSep 2, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 10, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 10, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 11, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
    EDGAR ↗

About Cogent Biosciences, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersWALTHAM, MA
IncorporatedDE
Former namesUnum Therapeutics Inc., Unum Therapeutics, Inc.